Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Pol

Showing results (381-390 of 441) with videos related to

Pageof 45
Sort By:
Gastroenterology|November 5, 2013
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infectionGregory T Everson, Karen D Sims, Maribel Rodriguez-Torres, et al.
Elife|November 17, 2015
Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patientsCécile Alanio, Francesco Nicoli, Philippe Sultanik, et al.
Blood|September 9, 2016
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infectionLuca Arcaini, Caroline Besson, Marco Frigeni, et al.
The New England Journal of Medicine|June 24, 2011
Telaprevir for retreatment of HCV infectionStefan Zeuzem, Pietro Andreone, Stanislas Pol, et al.
Hepatology (Baltimore, Md.)|December 20, 2011
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypesPierre-Yves Bochud, Stéphanie Bibert, Zoltán Kutalik, et al.
Cytokine|May 4, 2021
Differential levels of IFNα subtypes in autoimmunity and viral infectionVincent Bondet, Mathieu P Rodero, Céline Posseme, et al.
Journal of Hepatology|October 11, 2015
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infectionStefan Zeuzem, Christophe Hézode, Jean-Pierre Bronowicki, et al.
American Journal of Hematology|November 25, 2014
Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C studyJean-Marie Michot, Danielle Canioni, Henda Driss, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 26, 2019
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized studyTarik Asselah, Stanislas Pol, Christophe Hezode, et al.
Alimentary Pharmacology & Therapeutics|August 16, 2021
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetesThierry Poynard, Valérie Paradis, Jimmy Mullaert, et al.
Pageof 45

Showing results (381-390 of 441) with videos related to

Sort By:
Pageof 45
Gastroenterology|November 5, 2013
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infectionGregory T Everson, Karen D Sims, Maribel Rodriguez-Torres, et al.
Elife|November 17, 2015
Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patientsCécile Alanio, Francesco Nicoli, Philippe Sultanik, et al.
Blood|September 9, 2016
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infectionLuca Arcaini, Caroline Besson, Marco Frigeni, et al.
The New England Journal of Medicine|June 24, 2011
Telaprevir for retreatment of HCV infectionStefan Zeuzem, Pietro Andreone, Stanislas Pol, et al.
Hepatology (Baltimore, Md.)|December 20, 2011
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypesPierre-Yves Bochud, Stéphanie Bibert, Zoltán Kutalik, et al.
Cytokine|May 4, 2021
Differential levels of IFNα subtypes in autoimmunity and viral infectionVincent Bondet, Mathieu P Rodero, Céline Posseme, et al.
Journal of Hepatology|October 11, 2015
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infectionStefan Zeuzem, Christophe Hézode, Jean-Pierre Bronowicki, et al.
American Journal of Hematology|November 25, 2014
Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C studyJean-Marie Michot, Danielle Canioni, Henda Driss, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 26, 2019
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized studyTarik Asselah, Stanislas Pol, Christophe Hezode, et al.
Alimentary Pharmacology & Therapeutics|August 16, 2021
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetesThierry Poynard, Valérie Paradis, Jimmy Mullaert, et al.
Pageof 45